The company also said it is aiming to expand its direct sales and marketing team by mid-year.
Meanwhile, the company is moving ahead with a clinical trial to support the assay's approval in the US.
The method could potentially be useful as a companion diagnostic for targeted drug therapies.
DiaCarta will have the exclusive rights to develop a test for the early detection of colon cancer from stool samples and to commercialize it globally.
The revenue increase is driven by the placement of 22 XT-8 analyzers in the US during the period.
In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.
Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.
FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.
Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.